/PALI
PALI Stock - Palisade Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$1.83+9.58%
+$0.16 (+9.58%) • Dec 19
44
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.73
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).14
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-18.0%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PALI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.81 – $1.85
TARGET (TP)$1.50
STOP LOSS$1.68
RISK/REWARD1:-2.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.64
52W High$2.59
52W Low$0.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $250,000 | N/A | N/A | N/A |
| Gross Profit | N/A | $250,000 | N/A | N/A | $-146,000 |
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A |
| Operating Income | $-14,859,000 | $-13,070,000 | $-15,721,000 | $-41,854,000 | $-9,297,000 |
| Net Income | $-14,438,000 | $-12,300,000 | $-14,260,000 | $-26,616,000 | $-10,322,000 |
| Net Margin | N/A | -4920.0% | N/A | N/A | N/A |
| EPS | $-10.19 | $-27.01 | $-16.53 | $-2144.25 | $-186.00 |
Company Overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PALIBeat Rate
47%
Last 17 quarters
Avg Surprise
-157.0%
EPS vs Estimate
Beats / Misses
8/9
Last 12 quarters
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
+27.5%
$-3.75vs$-5.17
Q2 24
+4.4%
$-4.59vs$-4.80
Q3 24
-13.3%
$-3.32vs$-2.93
Q4 24
+30.7%
$-2.32vs$-3.35
Q1 25
+65.3%
$-0.69vs$-1.99
Q2 25
+44.0%
$-0.47vs$-0.84
Q3 25
-20.8%
$-0.58vs$-0.48
Q4 25
-18.8%
$-0.38vs$-0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.01 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.32 | $-0.38 | -18.8% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.48 | $-0.58 | -20.8% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.84 | $-0.47 | +44.0% | ✓ BEAT |
Q1 2025 | Mar 24, 2025 | $-1.99 | $-0.69 | +65.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-3.35 | $-2.32 | +30.7% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-2.93 | $-3.32 | -13.3% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-4.80 | $-4.59 | +4.4% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $-5.17 | $-3.75 | +27.5% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.39 | $-7.35 | -1784.6% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.45 | $-7.95 | -1666.7% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.72 | $-8.10 | -1025.0% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-2.43 | $6.47 | +366.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-4.00 | $-59.97 | -1399.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-8.50 | $-89.96 | -958.4% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-210.00 | $-194.90 | +7.2% | ✓ BEAT |
Q1 2022 | Mar 16, 2022 | $-11.75 | $554.72 | +4821.0% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-18.00 | $-224.89 | -1149.4% | ✗ MISS |
Q3 2021 | Aug 24, 2021 | — | $-3073.46 | — | — |
Q2 2021 | May 14, 2021 | — | $-16.98 | — | — |
Latest News
Palisade Bio Q3 EPS $(0.38) Misses $(0.27) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 10:50 PM
Palisade Bio Doses The First Patients In Its Phase 1b Study Of PALI-2108, A First-In-Class Ileocolonic-Targeted PDE4 Inhibitor Prodrug For Fibrostenotic Crohn's Disease—A Condition With No Approved Therapies
📈 PositiveBenzinga•Oct 20, 2025, 12:48 PM
Palisade Bio Secures Canadian Patent For PALI-2108, Gut-Activated PDE4 B/D Inhibitor Targeting FSCD And UC
📈 PositiveBenzinga•Oct 13, 2025, 12:49 PM
PALI stock has given up its prior loss. Palisade Bio shares were trading lower after the company priced a $120M public offering of 171.4M shares at $0.70 per share.
➖ NeutralBenzinga•Oct 1, 2025, 01:54 PM
Palisade Bio shares are trading lower after the company priced a $120M public offering of 171.4M shares at $0.70 per share.
📉 NegativeBenzinga•Oct 1, 2025, 01:24 PM
Palisade Bio Prices $120M Public Offering Of 171,440,559 Shares At $0.70/Share
📉 NegativeBenzinga•Oct 1, 2025, 01:21 PM
Palisade Bio Adjourns Special Stockholder Meeting Due To Lack Of Quorum
📉 NegativeBenzinga•Sep 18, 2025, 08:08 PM
Palisade Bio Releases PALI-2108 Phase 1b Clinical Data Demonstrating 100% Clinical Response Regarding Efficacy Of PALI-2108 In Ulcerative Colitis
📈 PositiveBenzinga•Sep 17, 2025, 01:05 PM
PALI stock has given up its prior gain. Palisade Bio shares were trading higher after the company received Health Canada clearance to initiate a Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease.
➖ NeutralBenzinga•Sep 5, 2025, 02:38 PM
Palisade Bio shares are trading higher after the company received Health Canada clearance to initiate a Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease.
📈 PositiveBenzinga•Sep 5, 2025, 12:51 PM
Palisade Bio Receives Health Canada Clearance To Initiate Phase 1b Study Of PALI-2108 In Fibrostenotic Crohn's Disease
📈 PositiveBenzinga•Sep 5, 2025, 12:47 PM
Frequently Asked Questions about PALI
What is PALI's current stock price?
Palisade Bio, Inc. (PALI) is currently trading at $1.83 per share. The stock has moved +9.58% today.
What is the analyst price target for PALI?
The average analyst price target for PALI is $1.50, based on 1 analyst.
What sector is Palisade Bio, Inc. in?
Palisade Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PALI's market cap?
Palisade Bio, Inc. has a market capitalization of $0.27 billion, making it a small-cap company.
Does PALI pay dividends?
No, Palisade Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
HOTH
Hoth Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to PALI for comparison